Skip to main content
. 2020 Nov 16;2:602236. doi: 10.3389/fmedt.2020.602236

Table 4.

Comparison of AAV and THL intravenous gene therapy of brain.

Property AAV THL References
Immunogenicity High Low (13, 297)
Frequency of administration Single Chronic (54, 297, 303)
Transfection of brain cells <30% 100% (8, 9, 54, 256)
Injection dose (vg/kg) 1014 1012 (10, 50)
Size limitation of therapeutic gene 2–4 kb >20 kb (9, 68)
Chromosomal integration At high doses None (11, 12, 256)